Thu, May 15, 9:24 PM (28 days ago)
**Longevity Health Holdings, Inc. (XAGE) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** $534.943K, driven by Elevai Acquisition sales. - **Net Loss:** $1.505M, improved from $3.270M in Q1 2024. - **Cash Flow:** Negative $752.953K from operations, improved from $1.075M in Q1 2024. - **Liquidity:** $770.047K in cash, negative working capital of $3.805M. **Profit Margins & Expenses:** - **Gross Margin:** 50.44%. - **Operating Margin:** -283.38%. - **Selling & Marketing:** $280.549K, up from $0 in Q1 2024. - **R&D:** $196.912K, down from $429.420K in Q1 2024. - **G&A:** $1.275M, up from $927.394K in Q1 2024. **Key Metrics & Trends:** - **Elevai Acquisition:** Completed on Jan 16, 2025, with $2.5M in 2024 revenue. - **Private Placement:** $1.85M raised in Jan 2025. - **Reverse Stock Split:** 1:30 ratio, reducing shares from ~30.1M to ~1M. - **Nasdaq Delisting:** Non-compliance with MVLS and Minimum Bid Price Requirements, appeal pending. - **Going Concern:** Substantial doubt about the ability to continue as a going concern. **Uncertainties & Future Operations:** - **Merger:** Pending with 20/20 Biolabs, requiring $4M in concurrent financing. - **Legal Proceedings:** Ongoing litigation with Puritan Partners LLC. - **Capital Raising:** Exploring additional financing and out-licensing R&D programs. **Outlook:** - Focus on cosmetic skincare and haircare products. - Cost-saving measures and restructuring efforts. - Uncertainty due to pending merger, legal proceedings, and capital raising needs.